FMC63 is a mouse-derived monoclonal antibody that recognizes CD19, a protein found on the surface of B cells, and it has become the single most influential binding domain in the history of engineered cell therapy. The antibody’s antigen-recognition fragment sits at the heart of several approved CAR-T cell products used to treat blood cancers, and it is now being tested in autoimmune diseases like lupus. Yet FMC63’s dominance also means that its limitations shape the field’s biggest challenges, from tumor resistance to immune rejection of the therapy itself.
What FMC63 Actually Is
FMC63 is an IgG2a mouse monoclonal antibody that belongs to the CD19 cluster, meaning it binds the CD19 protein expressed on cells of the B lymphocyte lineage, from early pre-B cells through mature B lymphocytes.1PubMed. Preparation and characterization of a chimeric CD19 monoclonal antibody CD19 is a roughly 95-kilodalton surface protein that serves as a co-receptor on B cells, making it a near-universal marker for the B-cell lineage. Because B cells are central players in both blood cancers and antibody-driven autoimmune diseases, a reliable way to target them has enormous therapeutic value. FMC63 provided exactly that.
The antibody was originally generated in a mouse immunized with human B cells, then selected for its strong and specific reactivity with CD19. What made FMC63 special was not just that it bound CD19, but that it bound it in a way that lent itself well to engineering. Researchers could take the variable regions of FMC63, the parts responsible for recognizing CD19, and graft them into a single-chain variable fragment (scFv). That scFv could then be fused to signaling machinery inside a T cell, creating what is now known as a chimeric antigen receptor, or CAR.
Where FMC63 Grabs CD19
Understanding exactly where FMC63 contacts CD19 matters because the binding site, or epitope, determines both the antibody’s effectiveness and the ways tumors can evade it. The FMC63 epitope is conformational, meaning it depends on the three-dimensional shape of CD19 rather than a simple linear stretch of amino acids. Specifically, the epitope spans loops encoded by exons 3 and 4 of the CD19 gene, which are genetically distant on the DNA but sit close together once the protein folds.2PubMed. Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design Both exons are essential for FMC63 recognition, so a mutation disrupting either one can abolish binding.
Researchers have now visualized the FMC63-CD19 complex at atomic resolution using cryo-electron microscopy, solving the structure to about 3 angstroms.3PubMed Central. CD19 CAR antigen engagement mechanisms and affinity tuning That structural picture has been crucial for understanding how affinity tuning works and for designing next-generation CARs that might engage CD19 differently. Surface plasmon resonance measurements, often considered the gold standard for binding affinity, put FMC63’s affinity for CD19 at about 5 nanomolar, with relatively slow dissociation from the target.4Scientific Reports. Solving the mystery of the FMC63-CD19 affinity That tight grip is part of what makes FMC63-based CARs effective, though as we will see, it also creates some tradeoffs.
FMC63 in CAR-T Cell Therapy for Blood Cancers
The therapeutic impact of FMC63 is hard to overstate. CAR-T cell therapies targeting CD19 through FMC63’s scFv achieve complete remission rates in the range of 70% to 90% in patients with relapsed or treatment-resistant B-cell acute lymphoblastic leukemia (B-ALL), a population that previously had very few options.5Blood. Phase 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL) Several commercially approved products, including tisagenlecleucel and axicabtagene ciloleucel, use the FMC63 scFv as their tumor-targeting component.
The CAR construct built around FMC63 typically pairs the scFv with intracellular signaling domains that tell the T cell to activate and kill. A key design choice is which costimulatory domain to include alongside the primary activation signal. A comparison of CARs using the 4-1BB costimulatory domain versus the CD28 domain found similar antitumor effectiveness, with both achieving a complete response rate of about 67% within three months in patients with B-cell non-Hodgkin lymphoma. However, the CD28-containing CAR triggered more severe side effects, including cytokine release syndrome and neurotoxicity serious enough to halt further testing of that arm.6Molecular Therapy Oncology. Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma This finding helped shape the field’s preference for 4-1BB costimulation in many CD19 CAR designs, though CD28-based products remain in use for certain indications.
How Tumors Learn to Hide from FMC63
Despite the impressive initial response rates, a significant fraction of patients relapse after FMC63-based CAR-T therapy, and the mechanisms of escape trace directly back to the biology of the FMC63 epitope. Because FMC63 recognizes a conformational epitope requiring both exons 3 and 4, tumors have multiple genetic routes to disrupt that binding site. Researchers have found point mutations in the FMC63 epitope coding region in tumor cells that survived CAR-T attack, including a single-base deletion in exon 3 that caused a frameshift and premature termination of CD19, effectively erasing the epitope entirely. In one cell line, the variant allele frequency for this mutation reached 95%, suggesting the tumor had also lost the remaining normal copy of the gene.7PubMed Central. The costimulatory domain influences CD19 CAR-T cell resistance development in B-cell malignancies
Mutation is only one escape route. An equally sophisticated mechanism involves alternative splicing of CD19 messenger RNA. In relapsed patients, researchers discovered CD19 mRNA species missing exon 2, producing a truncated version of the CD19 protein that still partially functions for the B cell but no longer triggers killing by FMC63-based CAR-T cells. The levels of a splicing factor called SRSF3, which normally helps retain exon 2, were lower in relapsed samples. Using genome editing, the team showed that exon 2 skipping could bypass even pre-existing exon 2 mutations, allowing expression of the truncated variant. The result is a double hit: harmful mutations arise under the selective pressure of CAR-T therapy, and the splicing machinery then routes around them to keep CD19 partially expressed in a form the therapy cannot see.8Cancer Discovery. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Interestingly, the costimulatory domain chosen in the CAR construct may also influence resistance. In one study, CD19 mutations in the FMC63 epitope region appeared in cells exposed to 4-1BB-containing CARs but not in those exposed to CD28-containing CARs, raising the possibility that the slower, more persistent selective pressure of 4-1BB costimulation gives tumors more time to evolve escape mutations.7PubMed Central. The costimulatory domain influences CD19 CAR-T cell resistance development in B-cell malignancies This is still an early observation, but it adds another dimension to CAR design decisions.
The Push to Humanize or Replace FMC63
FMC63 comes from a mouse, and that is a problem. When a patient receives CAR-T cells bearing a mouse-derived scFv, their immune system can recognize those mouse protein sequences as foreign and mount an anti-drug antibody response. This can neutralize the therapy, shorten how long the CAR-T cells persist, and potentially cause allergic reactions on retreatment. The concern has driven two parallel efforts: humanizing FMC63 itself, and developing fully human alternatives.
Humanization takes the critical binding loops from FMC63 and grafts them onto a human antibody framework, keeping the targeting function while reducing the foreign protein content. One group produced humanized variants called VH4vκ1 and 4D5, both of which showed weaker binding affinity than the original FMC63 scFv.9Blood Neoplasia. Development and characterization of a low-affinity humanized CD19 chimeric antigen receptor for B-cell malignancies Lower affinity might sound like a disadvantage, but there is growing evidence that slightly weaker binding can actually improve CAR-T cell function by reducing exhaustion and overstimulation. In a clinical trial using a low-affinity CD19 CAR called CAT, 12 of 14 children with relapsed B-ALL achieved molecular remission, with enhanced CAR-T cell expansion and low toxicity. One-year overall survival was 63%, and no severe cytokine release syndrome was observed.10Nature Medicine. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
Separately, researchers constructed two entirely humanized CD19-specific CARs derived from different antibody clones and compared them head-to-head with FMC63-based CARs. The humanized versions showed comparable potency in preclinical testing, providing a basis for clinical trials that could sidestep immune rejection of mouse-derived sequences.11Blood. Construction and Testing of Two Distinct Humanized CD19-Specific Chimeric Antigen Receptors (CARs) for the Treatment of B-Cell Malignancies Meanwhile, an even more ambitious approach bypasses FMC63 altogether. Fully human CD19-specific scFvs have been generated through phage display libraries, and in preclinical testing several of these outperformed FMC63 in killing tumor cells, producing cytokines, and eliminating lymphoma in animal models.12PubMed Central. Fully human CD19-specific chimeric antigen receptors for T-cell therapy These fully human CARs are not yet in wide clinical use, but they represent a clear direction for the field.
FMC63 Beyond Cancer
One of the most exciting recent developments is the use of FMC63-based CAR-T cells to treat autoimmune diseases. The logic is straightforward: if B cells are producing the harmful autoantibodies that drive diseases like systemic lupus erythematosus (SLE), then depleting those B cells should quiet the disease. Conventional B-cell-depleting drugs like rituximab work on a similar principle but target CD20 rather than CD19 and often fail in severe lupus.
In a compassionate-use program, five patients with severe, treatment-resistant lupus received autologous CAR-T cells transduced with an anti-CD19 CAR vector based on FMC63. The CAR-T cells expanded in the patients’ bodies, drove B-cell counts to near zero, and produced striking clinical improvements. All five patients achieved remission within three months, with a median disease activity score dropping to zero. Remarkably, this drug-free remission persisted even after B cells began returning, on average about 110 days after treatment. The returning B cells were naïve, carrying non-class-switched receptors, suggesting a kind of immune “reset” rather than a return to the pre-treatment state. Side effects were mild, limited to low-grade cytokine release syndrome.13Nature Medicine. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
These results, while from a very small group, have generated enormous enthusiasm. Larger trials are underway. If the approach holds up, FMC63-based CAR-T therapy could transform the treatment of not just lupus but potentially other autoantibody-mediated conditions like systemic sclerosis and inflammatory myopathies. The fact that remission continued after B-cell reconstitution is particularly encouraging, because it implies the therapy may break a self-perpetuating cycle of autoimmunity rather than simply suppressing it temporarily.14PubMed Central. Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus
Dual-Targeting and Multispecific Designs
The resistance problem described earlier has pushed researchers toward strategies that do not rely on CD19 alone. A leading approach is to target CD19 and CD22 simultaneously, since CD22 is another B-cell surface protein that tends to persist even when CD19 is lost or mutated. Several dual-targeting strategies incorporate FMC63 as the CD19-binding component.
One design uses a bispecific CAR in which FMC63’s scFv and a separate CD22-binding domain are combined into a single receptor. In a phase I trial of a CD19/CD22 bispecific CAR in patients with ALL, 11 of 12 evaluable patients achieved complete remission by day 28.15Blood. Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia Another approach co-transduces T cells with two separate CAR constructs, one targeting CD19 (often using FMC63) and one targeting CD22, so that a single T cell carries receptors for both antigens.16PubMed Central. Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR
Researchers have also explored creative structural formats. Loop-type bispecific CARs thread a second binding domain into the architecture of the first, and several of these incorporate FMC63 alongside different CD22 binders.17Protein & Cell. A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignancies Beyond CARs, FMC63 has been built into trispecific antibodies. One such molecule combines an FMC63-derived anti-CD19 scFv, an anti-CD22 nanobody, and a CD3-binding fragment that recruits T cells, creating a single soluble protein that bridges tumor cells and killer T cells through two independent tumor targets.18Blood. A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL These multispecific designs aim to make antigen-loss escape harder by requiring the tumor to lose two surface proteins simultaneously.
Tracking FMC63-Based CAR-T Cells in Patients
Once CAR-T cells are infused into a patient, clinicians need to track them: Are they expanding? Are they persisting? Are they becoming exhausted? Because FMC63 is so widely used, anti-idiotype antibodies have been developed that specifically recognize the FMC63-derived scFv on CAR-T cell surfaces. These reagents allow flow cytometry panels to distinguish CAR-T cells from normal T cells in a blood sample.19PubMed Central. Quantification and Immunophenotypic Characterisation of CAR T-Cells by Flow Cytometry and Correlation with Clinical Outcomes for Patients with Large B Cell Lymphoma
In practice, an anti-FMC63 antibody is included alongside markers for T-cell subsets, activation status, and exhaustion markers like PD-1 and TIGIT. This combination lets researchers and clinicians build a detailed picture of the CAR-T cell population over time and correlate it with clinical response. The approach works specifically because so many commercial and academic CAR-T products share the FMC63 recognition domain, making a single detection reagent broadly useful.20PubMed Central. Time to evolve: predicting engineered T cell-associated toxicity with next-generation models For CAR constructs built on non-FMC63 scFvs, new detection antibodies must be developed from scratch, which adds cost and time to clinical monitoring.
FMC63 in Bispecific Antibody Platforms
FMC63’s influence extends well beyond CAR-T cells. Bispecific T-cell engagers (BiTEs) and related formats redirect a patient’s own T cells to kill tumor cells without requiring the complex manufacturing process of harvesting, engineering, and expanding a patient’s T cells ex vivo. Several groups have taken FMC63’s binding sequences and incorporated them into these off-the-shelf bispecific platforms.
To make these molecules suitable for human use, FMC63’s mouse sequences are typically humanized by grafting the complementarity-determining regions (the loops that directly contact CD19) onto human antibody framework scaffolds. One team humanized FMC63 by placing its heavy-chain binding loops onto a human IGHV4-4 framework and its light-chain loops onto a human IGKV1-33 framework, then used the resulting humanized scFv to build bispecific antibodies combining CD19 targeting with engagement of other surface proteins.21PubMed Central. Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies These bispecific designs share the dual-targeting philosophy of the CAR approaches described earlier but in a drug format that could be administered directly from a vial, without the weeks-long cell manufacturing process that CAR-T therapy requires. They represent another way FMC63’s binding specificity continues to seed new therapeutic strategies, even as the field works to move beyond the original mouse antibody itself.